** Shares of medtech firm Glaukos Corp GKOS.N rise 3.3% to $158 premarket
** Brokerage Mizuho upgrades rating on GKOS to "outperform" from "neutral", citing its "disruptive potential" in the US glaucoma market
** Also raises PT to $200 from $140; representing a 30.8% upside to the stock's last close
** Brokerage says it believes iDose has a "substantial lead" in the drug-device combo setting and can drive up to $7 in adjusted EPS by 2030
** iDose is a device that helps lower eye pressure in people with glaucoma, a disease that damages the optic nerve, by slowly releasing medicine
** Expects iDose sales to reach over $1 bln by 2029, driven by a "favorable US adoption cycle with expanded coverage over the next several years"
** Says iDose has a unique advantage over competing products, such as Abbvie's ABBV.N Durysta implant, due to its "reservoir design that allows for continuous drug elution up to 3 years"
** GKOS gained 94.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。